The development of a targeted approach to investigating ctDNA, which studies known genetic mutations located in specific genes, has led to important progress for targeted therapies, such as the ability to predict therapeutic response to the EGFR inhibition in lung cancer by analyzing specific mutations of this gene [11, 20, 21]. This evidence concerns the gene EGFR and lung cancer.